Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
14,731
archived clinical trials in
Psychiatric

Dose-optimization in Adolescents Aged 13-17 Diagnosed With Attention-deficit/Hyperactivity Disorder (ADHD) Using Extended-release Guanfacine HCl
A Phase 3, Double-blind, Randomized, Multi-center, Placebo Controlled, Dose-optimization Study Evaluating the Safety, Efficacy, and Tolerability of Once Daily Dosing With Extended-release Guanfacine Hydrochloride in Adolescents Aged 13-17 Years Diagnosed With Attention-deficit/Hyperactivity Disorder (ADHD)
Status: Enrolling
Updated:  11/5/2012
OCCI, Inc.
mi
from
Portland, OR
Dose-optimization in Adolescents Aged 13-17 Diagnosed With Attention-deficit/Hyperactivity Disorder (ADHD) Using Extended-release Guanfacine HCl
A Phase 3, Double-blind, Randomized, Multi-center, Placebo Controlled, Dose-optimization Study Evaluating the Safety, Efficacy, and Tolerability of Once Daily Dosing With Extended-release Guanfacine Hydrochloride in Adolescents Aged 13-17 Years Diagnosed With Attention-deficit/Hyperactivity Disorder (ADHD)
Status: Enrolling
Updated: 11/5/2012
OCCI, Inc.
mi
from
Portland, OR
Click here to add this to my saved trials
Dose-optimization in Adolescents Aged 13-17 Diagnosed With Attention-deficit/Hyperactivity Disorder (ADHD) Using Extended-release Guanfacine HCl
A Phase 3, Double-blind, Randomized, Multi-center, Placebo Controlled, Dose-optimization Study Evaluating the Safety, Efficacy, and Tolerability of Once Daily Dosing With Extended-release Guanfacine Hydrochloride in Adolescents Aged 13-17 Years Diagnosed With Attention-deficit/Hyperactivity Disorder (ADHD)
Status: Enrolling
Updated:  11/5/2012
Oregon Center for Clinical Investigations, Inc.
mi
from
Portland, OR
Dose-optimization in Adolescents Aged 13-17 Diagnosed With Attention-deficit/Hyperactivity Disorder (ADHD) Using Extended-release Guanfacine HCl
A Phase 3, Double-blind, Randomized, Multi-center, Placebo Controlled, Dose-optimization Study Evaluating the Safety, Efficacy, and Tolerability of Once Daily Dosing With Extended-release Guanfacine Hydrochloride in Adolescents Aged 13-17 Years Diagnosed With Attention-deficit/Hyperactivity Disorder (ADHD)
Status: Enrolling
Updated: 11/5/2012
Oregon Center for Clinical Investigations, Inc.
mi
from
Portland, OR
Click here to add this to my saved trials
Dose-optimization in Adolescents Aged 13-17 Diagnosed With Attention-deficit/Hyperactivity Disorder (ADHD) Using Extended-release Guanfacine HCl
A Phase 3, Double-blind, Randomized, Multi-center, Placebo Controlled, Dose-optimization Study Evaluating the Safety, Efficacy, and Tolerability of Once Daily Dosing With Extended-release Guanfacine Hydrochloride in Adolescents Aged 13-17 Years Diagnosed With Attention-deficit/Hyperactivity Disorder (ADHD)
Status: Enrolling
Updated:  11/5/2012
CRI Worldwide, LLC
mi
from
Philadelphia, PA
Dose-optimization in Adolescents Aged 13-17 Diagnosed With Attention-deficit/Hyperactivity Disorder (ADHD) Using Extended-release Guanfacine HCl
A Phase 3, Double-blind, Randomized, Multi-center, Placebo Controlled, Dose-optimization Study Evaluating the Safety, Efficacy, and Tolerability of Once Daily Dosing With Extended-release Guanfacine Hydrochloride in Adolescents Aged 13-17 Years Diagnosed With Attention-deficit/Hyperactivity Disorder (ADHD)
Status: Enrolling
Updated: 11/5/2012
CRI Worldwide, LLC
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Dose-optimization in Adolescents Aged 13-17 Diagnosed With Attention-deficit/Hyperactivity Disorder (ADHD) Using Extended-release Guanfacine HCl
A Phase 3, Double-blind, Randomized, Multi-center, Placebo Controlled, Dose-optimization Study Evaluating the Safety, Efficacy, and Tolerability of Once Daily Dosing With Extended-release Guanfacine Hydrochloride in Adolescents Aged 13-17 Years Diagnosed With Attention-deficit/Hyperactivity Disorder (ADHD)
Status: Enrolling
Updated:  11/5/2012
University Services Sleep Diagnostic and Treatment Centers
mi
from
West Chester, PA
Dose-optimization in Adolescents Aged 13-17 Diagnosed With Attention-deficit/Hyperactivity Disorder (ADHD) Using Extended-release Guanfacine HCl
A Phase 3, Double-blind, Randomized, Multi-center, Placebo Controlled, Dose-optimization Study Evaluating the Safety, Efficacy, and Tolerability of Once Daily Dosing With Extended-release Guanfacine Hydrochloride in Adolescents Aged 13-17 Years Diagnosed With Attention-deficit/Hyperactivity Disorder (ADHD)
Status: Enrolling
Updated: 11/5/2012
University Services Sleep Diagnostic and Treatment Centers
mi
from
West Chester, PA
Click here to add this to my saved trials
Dose-optimization in Adolescents Aged 13-17 Diagnosed With Attention-deficit/Hyperactivity Disorder (ADHD) Using Extended-release Guanfacine HCl
A Phase 3, Double-blind, Randomized, Multi-center, Placebo Controlled, Dose-optimization Study Evaluating the Safety, Efficacy, and Tolerability of Once Daily Dosing With Extended-release Guanfacine Hydrochloride in Adolescents Aged 13-17 Years Diagnosed With Attention-deficit/Hyperactivity Disorder (ADHD)
Status: Enrolling
Updated:  11/5/2012
Rainbow Research
mi
from
Barnwell, SC
Dose-optimization in Adolescents Aged 13-17 Diagnosed With Attention-deficit/Hyperactivity Disorder (ADHD) Using Extended-release Guanfacine HCl
A Phase 3, Double-blind, Randomized, Multi-center, Placebo Controlled, Dose-optimization Study Evaluating the Safety, Efficacy, and Tolerability of Once Daily Dosing With Extended-release Guanfacine Hydrochloride in Adolescents Aged 13-17 Years Diagnosed With Attention-deficit/Hyperactivity Disorder (ADHD)
Status: Enrolling
Updated: 11/5/2012
Rainbow Research
mi
from
Barnwell, SC
Click here to add this to my saved trials
Dose-optimization in Adolescents Aged 13-17 Diagnosed With Attention-deficit/Hyperactivity Disorder (ADHD) Using Extended-release Guanfacine HCl
A Phase 3, Double-blind, Randomized, Multi-center, Placebo Controlled, Dose-optimization Study Evaluating the Safety, Efficacy, and Tolerability of Once Daily Dosing With Extended-release Guanfacine Hydrochloride in Adolescents Aged 13-17 Years Diagnosed With Attention-deficit/Hyperactivity Disorder (ADHD)
Status: Enrolling
Updated:  11/5/2012
Jackson Clinic
mi
from
Jackson, TN
Dose-optimization in Adolescents Aged 13-17 Diagnosed With Attention-deficit/Hyperactivity Disorder (ADHD) Using Extended-release Guanfacine HCl
A Phase 3, Double-blind, Randomized, Multi-center, Placebo Controlled, Dose-optimization Study Evaluating the Safety, Efficacy, and Tolerability of Once Daily Dosing With Extended-release Guanfacine Hydrochloride in Adolescents Aged 13-17 Years Diagnosed With Attention-deficit/Hyperactivity Disorder (ADHD)
Status: Enrolling
Updated: 11/5/2012
Jackson Clinic
mi
from
Jackson, TN
Click here to add this to my saved trials
Dose-optimization in Adolescents Aged 13-17 Diagnosed With Attention-deficit/Hyperactivity Disorder (ADHD) Using Extended-release Guanfacine HCl
A Phase 3, Double-blind, Randomized, Multi-center, Placebo Controlled, Dose-optimization Study Evaluating the Safety, Efficacy, and Tolerability of Once Daily Dosing With Extended-release Guanfacine Hydrochloride in Adolescents Aged 13-17 Years Diagnosed With Attention-deficit/Hyperactivity Disorder (ADHD)
Status: Enrolling
Updated:  11/5/2012
Clinical NeuroScience Solutions, Inc.
mi
from
Memphis, TN
Dose-optimization in Adolescents Aged 13-17 Diagnosed With Attention-deficit/Hyperactivity Disorder (ADHD) Using Extended-release Guanfacine HCl
A Phase 3, Double-blind, Randomized, Multi-center, Placebo Controlled, Dose-optimization Study Evaluating the Safety, Efficacy, and Tolerability of Once Daily Dosing With Extended-release Guanfacine Hydrochloride in Adolescents Aged 13-17 Years Diagnosed With Attention-deficit/Hyperactivity Disorder (ADHD)
Status: Enrolling
Updated: 11/5/2012
Clinical NeuroScience Solutions, Inc.
mi
from
Memphis, TN
Click here to add this to my saved trials
Dose-optimization in Adolescents Aged 13-17 Diagnosed With Attention-deficit/Hyperactivity Disorder (ADHD) Using Extended-release Guanfacine HCl
A Phase 3, Double-blind, Randomized, Multi-center, Placebo Controlled, Dose-optimization Study Evaluating the Safety, Efficacy, and Tolerability of Once Daily Dosing With Extended-release Guanfacine Hydrochloride in Adolescents Aged 13-17 Years Diagnosed With Attention-deficit/Hyperactivity Disorder (ADHD)
Status: Enrolling
Updated:  11/5/2012
Research Strategies of Memphis, LLC
mi
from
Memphis, TN
Dose-optimization in Adolescents Aged 13-17 Diagnosed With Attention-deficit/Hyperactivity Disorder (ADHD) Using Extended-release Guanfacine HCl
A Phase 3, Double-blind, Randomized, Multi-center, Placebo Controlled, Dose-optimization Study Evaluating the Safety, Efficacy, and Tolerability of Once Daily Dosing With Extended-release Guanfacine Hydrochloride in Adolescents Aged 13-17 Years Diagnosed With Attention-deficit/Hyperactivity Disorder (ADHD)
Status: Enrolling
Updated: 11/5/2012
Research Strategies of Memphis, LLC
mi
from
Memphis, TN
Click here to add this to my saved trials
Dose-optimization in Adolescents Aged 13-17 Diagnosed With Attention-deficit/Hyperactivity Disorder (ADHD) Using Extended-release Guanfacine HCl
A Phase 3, Double-blind, Randomized, Multi-center, Placebo Controlled, Dose-optimization Study Evaluating the Safety, Efficacy, and Tolerability of Once Daily Dosing With Extended-release Guanfacine Hydrochloride in Adolescents Aged 13-17 Years Diagnosed With Attention-deficit/Hyperactivity Disorder (ADHD)
Status: Enrolling
Updated:  11/5/2012
FutureSearch Trials
mi
from
Dallas, TX
Dose-optimization in Adolescents Aged 13-17 Diagnosed With Attention-deficit/Hyperactivity Disorder (ADHD) Using Extended-release Guanfacine HCl
A Phase 3, Double-blind, Randomized, Multi-center, Placebo Controlled, Dose-optimization Study Evaluating the Safety, Efficacy, and Tolerability of Once Daily Dosing With Extended-release Guanfacine Hydrochloride in Adolescents Aged 13-17 Years Diagnosed With Attention-deficit/Hyperactivity Disorder (ADHD)
Status: Enrolling
Updated: 11/5/2012
FutureSearch Trials
mi
from
Dallas, TX
Click here to add this to my saved trials
Dose-optimization in Adolescents Aged 13-17 Diagnosed With Attention-deficit/Hyperactivity Disorder (ADHD) Using Extended-release Guanfacine HCl
A Phase 3, Double-blind, Randomized, Multi-center, Placebo Controlled, Dose-optimization Study Evaluating the Safety, Efficacy, and Tolerability of Once Daily Dosing With Extended-release Guanfacine Hydrochloride in Adolescents Aged 13-17 Years Diagnosed With Attention-deficit/Hyperactivity Disorder (ADHD)
Status: Enrolling
Updated:  11/5/2012
InSite Clinical Research
mi
from
Southwest, TX
Dose-optimization in Adolescents Aged 13-17 Diagnosed With Attention-deficit/Hyperactivity Disorder (ADHD) Using Extended-release Guanfacine HCl
A Phase 3, Double-blind, Randomized, Multi-center, Placebo Controlled, Dose-optimization Study Evaluating the Safety, Efficacy, and Tolerability of Once Daily Dosing With Extended-release Guanfacine Hydrochloride in Adolescents Aged 13-17 Years Diagnosed With Attention-deficit/Hyperactivity Disorder (ADHD)
Status: Enrolling
Updated: 11/5/2012
InSite Clinical Research
mi
from
Southwest, TX
Click here to add this to my saved trials
Dose-optimization in Adolescents Aged 13-17 Diagnosed With Attention-deficit/Hyperactivity Disorder (ADHD) Using Extended-release Guanfacine HCl
A Phase 3, Double-blind, Randomized, Multi-center, Placebo Controlled, Dose-optimization Study Evaluating the Safety, Efficacy, and Tolerability of Once Daily Dosing With Extended-release Guanfacine Hydrochloride in Adolescents Aged 13-17 Years Diagnosed With Attention-deficit/Hyperactivity Disorder (ADHD)
Status: Enrolling
Updated:  11/5/2012
R/D Clinical Research, Inc.
mi
from
Lake Jackson, TX
Dose-optimization in Adolescents Aged 13-17 Diagnosed With Attention-deficit/Hyperactivity Disorder (ADHD) Using Extended-release Guanfacine HCl
A Phase 3, Double-blind, Randomized, Multi-center, Placebo Controlled, Dose-optimization Study Evaluating the Safety, Efficacy, and Tolerability of Once Daily Dosing With Extended-release Guanfacine Hydrochloride in Adolescents Aged 13-17 Years Diagnosed With Attention-deficit/Hyperactivity Disorder (ADHD)
Status: Enrolling
Updated: 11/5/2012
R/D Clinical Research, Inc.
mi
from
Lake Jackson, TX
Click here to add this to my saved trials
Dose-optimization in Adolescents Aged 13-17 Diagnosed With Attention-deficit/Hyperactivity Disorder (ADHD) Using Extended-release Guanfacine HCl
A Phase 3, Double-blind, Randomized, Multi-center, Placebo Controlled, Dose-optimization Study Evaluating the Safety, Efficacy, and Tolerability of Once Daily Dosing With Extended-release Guanfacine Hydrochloride in Adolescents Aged 13-17 Years Diagnosed With Attention-deficit/Hyperactivity Disorder (ADHD)
Status: Enrolling
Updated:  11/5/2012
Westex Clinical Investigations
mi
from
Lubbock, TX
Dose-optimization in Adolescents Aged 13-17 Diagnosed With Attention-deficit/Hyperactivity Disorder (ADHD) Using Extended-release Guanfacine HCl
A Phase 3, Double-blind, Randomized, Multi-center, Placebo Controlled, Dose-optimization Study Evaluating the Safety, Efficacy, and Tolerability of Once Daily Dosing With Extended-release Guanfacine Hydrochloride in Adolescents Aged 13-17 Years Diagnosed With Attention-deficit/Hyperactivity Disorder (ADHD)
Status: Enrolling
Updated: 11/5/2012
Westex Clinical Investigations
mi
from
Lubbock, TX
Click here to add this to my saved trials
Dose-optimization in Adolescents Aged 13-17 Diagnosed With Attention-deficit/Hyperactivity Disorder (ADHD) Using Extended-release Guanfacine HCl
A Phase 3, Double-blind, Randomized, Multi-center, Placebo Controlled, Dose-optimization Study Evaluating the Safety, Efficacy, and Tolerability of Once Daily Dosing With Extended-release Guanfacine Hydrochloride in Adolescents Aged 13-17 Years Diagnosed With Attention-deficit/Hyperactivity Disorder (ADHD)
Status: Enrolling
Updated:  11/5/2012
NeuroScience, Inc.
mi
from
Herndon, VA
Dose-optimization in Adolescents Aged 13-17 Diagnosed With Attention-deficit/Hyperactivity Disorder (ADHD) Using Extended-release Guanfacine HCl
A Phase 3, Double-blind, Randomized, Multi-center, Placebo Controlled, Dose-optimization Study Evaluating the Safety, Efficacy, and Tolerability of Once Daily Dosing With Extended-release Guanfacine Hydrochloride in Adolescents Aged 13-17 Years Diagnosed With Attention-deficit/Hyperactivity Disorder (ADHD)
Status: Enrolling
Updated: 11/5/2012
NeuroScience, Inc.
mi
from
Herndon, VA
Click here to add this to my saved trials
Dose-optimization in Adolescents Aged 13-17 Diagnosed With Attention-deficit/Hyperactivity Disorder (ADHD) Using Extended-release Guanfacine HCl
A Phase 3, Double-blind, Randomized, Multi-center, Placebo Controlled, Dose-optimization Study Evaluating the Safety, Efficacy, and Tolerability of Once Daily Dosing With Extended-release Guanfacine Hydrochloride in Adolescents Aged 13-17 Years Diagnosed With Attention-deficit/Hyperactivity Disorder (ADHD)
Status: Enrolling
Updated:  11/5/2012
Alliance Research Group
mi
from
Richmond, VA
Dose-optimization in Adolescents Aged 13-17 Diagnosed With Attention-deficit/Hyperactivity Disorder (ADHD) Using Extended-release Guanfacine HCl
A Phase 3, Double-blind, Randomized, Multi-center, Placebo Controlled, Dose-optimization Study Evaluating the Safety, Efficacy, and Tolerability of Once Daily Dosing With Extended-release Guanfacine Hydrochloride in Adolescents Aged 13-17 Years Diagnosed With Attention-deficit/Hyperactivity Disorder (ADHD)
Status: Enrolling
Updated: 11/5/2012
Alliance Research Group
mi
from
Richmond, VA
Click here to add this to my saved trials
Dose-optimization in Adolescents Aged 13-17 Diagnosed With Attention-deficit/Hyperactivity Disorder (ADHD) Using Extended-release Guanfacine HCl
A Phase 3, Double-blind, Randomized, Multi-center, Placebo Controlled, Dose-optimization Study Evaluating the Safety, Efficacy, and Tolerability of Once Daily Dosing With Extended-release Guanfacine Hydrochloride in Adolescents Aged 13-17 Years Diagnosed With Attention-deficit/Hyperactivity Disorder (ADHD)
Status: Enrolling
Updated:  11/5/2012
Northwest Clinical Research Center
mi
from
East Seattle, WA
Dose-optimization in Adolescents Aged 13-17 Diagnosed With Attention-deficit/Hyperactivity Disorder (ADHD) Using Extended-release Guanfacine HCl
A Phase 3, Double-blind, Randomized, Multi-center, Placebo Controlled, Dose-optimization Study Evaluating the Safety, Efficacy, and Tolerability of Once Daily Dosing With Extended-release Guanfacine Hydrochloride in Adolescents Aged 13-17 Years Diagnosed With Attention-deficit/Hyperactivity Disorder (ADHD)
Status: Enrolling
Updated: 11/5/2012
Northwest Clinical Research Center
mi
from
East Seattle, WA
Click here to add this to my saved trials
Dose-optimization in Adolescents Aged 13-17 Diagnosed With Attention-deficit/Hyperactivity Disorder (ADHD) Using Extended-release Guanfacine HCl
A Phase 3, Double-blind, Randomized, Multi-center, Placebo Controlled, Dose-optimization Study Evaluating the Safety, Efficacy, and Tolerability of Once Daily Dosing With Extended-release Guanfacine Hydrochloride in Adolescents Aged 13-17 Years Diagnosed With Attention-deficit/Hyperactivity Disorder (ADHD)
Status: Enrolling
Updated:  11/5/2012
East Side Therapeutic Resource
mi
from
Kirkland, WA
Dose-optimization in Adolescents Aged 13-17 Diagnosed With Attention-deficit/Hyperactivity Disorder (ADHD) Using Extended-release Guanfacine HCl
A Phase 3, Double-blind, Randomized, Multi-center, Placebo Controlled, Dose-optimization Study Evaluating the Safety, Efficacy, and Tolerability of Once Daily Dosing With Extended-release Guanfacine Hydrochloride in Adolescents Aged 13-17 Years Diagnosed With Attention-deficit/Hyperactivity Disorder (ADHD)
Status: Enrolling
Updated: 11/5/2012
East Side Therapeutic Resource
mi
from
Kirkland, WA
Click here to add this to my saved trials
Diversion to Treatment for Injection Drug Users Arrested for Possession of Heroin
Status: Enrolling
Updated:  11/6/2012
The Center for Learning and Health
mi
from
Baltimore, MD
Diversion to Treatment for Injection Drug Users Arrested for Possession of Heroin
Status: Enrolling
Updated: 11/6/2012
The Center for Learning and Health
mi
from
Baltimore, MD
Click here to add this to my saved trials
The Role of Antidepressants or Antipsychotics in Preventing Psychosis
The Role of Antidepressants or Antipsychotics in Preventing Psychosis
Status: Enrolling
Updated:  11/6/2012
St. Luke's Hospital
mi
from
New York, NY
The Role of Antidepressants or Antipsychotics in Preventing Psychosis
The Role of Antidepressants or Antipsychotics in Preventing Psychosis
Status: Enrolling
Updated: 11/6/2012
St. Luke's Hospital
mi
from
New York, NY
Click here to add this to my saved trials
RP5063 in Subjects With Schizophrenia or Schizoaffective Disorder
REFRESH : Randomized Double-blind, Placebo-controlled, Multicenter Trial to Assess the Safety and Efficacy of RP5063 in Subjects With an Acute Exacerbation of Schizophrenia or Schizoaffective Disorder
Status: Enrolling
Updated:  11/7/2012
Reviva site
mi
from
Philadelphia, PA
RP5063 in Subjects With Schizophrenia or Schizoaffective Disorder
REFRESH : Randomized Double-blind, Placebo-controlled, Multicenter Trial to Assess the Safety and Efficacy of RP5063 in Subjects With an Acute Exacerbation of Schizophrenia or Schizoaffective Disorder
Status: Enrolling
Updated: 11/7/2012
Reviva site
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Modafinil in the Treatment of PTSD (Posttraumatic Stress Disorder)
A Double-Blind, Placebo-Controlled Trial of Modafinil in OEF/OIF Combat Veterans With PTSD
Status: Enrolling
Updated:  11/9/2012
CAVHS Eugene Towbin VA Medical Center
mi
from
North Little Rock, AR
Modafinil in the Treatment of PTSD (Posttraumatic Stress Disorder)
A Double-Blind, Placebo-Controlled Trial of Modafinil in OEF/OIF Combat Veterans With PTSD
Status: Enrolling
Updated: 11/9/2012
CAVHS Eugene Towbin VA Medical Center
mi
from
North Little Rock, AR
Click here to add this to my saved trials
Effects of Citicoline on Brain Function and Behavior in Marijuana-Dependent Individuals
Cannabis Dependence: Imaging and Medication Development - 1
Status: Enrolling
Updated:  11/13/2012
McLean Hospital, Department of Psychiatry
mi
from
Belmont, MA
Effects of Citicoline on Brain Function and Behavior in Marijuana-Dependent Individuals
Cannabis Dependence: Imaging and Medication Development - 1
Status: Enrolling
Updated: 11/13/2012
McLean Hospital, Department of Psychiatry
mi
from
Belmont, MA
Click here to add this to my saved trials
Aggressive Fever Control With Intravenous Ibuprofen After Non-traumatic Brain Hemorrhage
Aggressive Fever Control With Intravenous Ibuprofen After Non-traumatic Brain Hemorrhage
Status: Enrolling
Updated:  11/13/2012
Columbia University Medical Center
mi
from
New York, NY
Aggressive Fever Control With Intravenous Ibuprofen After Non-traumatic Brain Hemorrhage
Aggressive Fever Control With Intravenous Ibuprofen After Non-traumatic Brain Hemorrhage
Status: Enrolling
Updated: 11/13/2012
Columbia University Medical Center
mi
from
New York, NY
Click here to add this to my saved trials
Open-label Extension Evaluating Methylphenidate Hydrochloride Modified Release in Adults With Attention Deficit/Hyperactivity Disorder
A 6-month, Open-label Extension to a 40-week, Randomized, Double-blind, Placebo-controlled, Multicenter Efficacy and Safety Study of Methylphenidate Hydrochloride Modified Release in the Treatment of Adult Patients With Childhood-onset ADHD
Status: Enrolling
Updated:  11/13/2012
Novartis Investigative Site
mi
from
Fayetteville, AR
Open-label Extension Evaluating Methylphenidate Hydrochloride Modified Release in Adults With Attention Deficit/Hyperactivity Disorder
A 6-month, Open-label Extension to a 40-week, Randomized, Double-blind, Placebo-controlled, Multicenter Efficacy and Safety Study of Methylphenidate Hydrochloride Modified Release in the Treatment of Adult Patients With Childhood-onset ADHD
Status: Enrolling
Updated: 11/13/2012
Novartis Investigative Site
mi
from
Fayetteville, AR
Click here to add this to my saved trials
Open-label Extension Evaluating Methylphenidate Hydrochloride Modified Release in Adults With Attention Deficit/Hyperactivity Disorder
A 6-month, Open-label Extension to a 40-week, Randomized, Double-blind, Placebo-controlled, Multicenter Efficacy and Safety Study of Methylphenidate Hydrochloride Modified Release in the Treatment of Adult Patients With Childhood-onset ADHD
Status: Enrolling
Updated:  11/13/2012
Novartis Investigative site
mi
from
Los Angeles, CA
Open-label Extension Evaluating Methylphenidate Hydrochloride Modified Release in Adults With Attention Deficit/Hyperactivity Disorder
A 6-month, Open-label Extension to a 40-week, Randomized, Double-blind, Placebo-controlled, Multicenter Efficacy and Safety Study of Methylphenidate Hydrochloride Modified Release in the Treatment of Adult Patients With Childhood-onset ADHD
Status: Enrolling
Updated: 11/13/2012
Novartis Investigative site
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Open-label Extension Evaluating Methylphenidate Hydrochloride Modified Release in Adults With Attention Deficit/Hyperactivity Disorder
A 6-month, Open-label Extension to a 40-week, Randomized, Double-blind, Placebo-controlled, Multicenter Efficacy and Safety Study of Methylphenidate Hydrochloride Modified Release in the Treatment of Adult Patients With Childhood-onset ADHD
Status: Enrolling
Updated:  11/13/2012
Novartis Investigative Site
mi
from
Miami, FL
Open-label Extension Evaluating Methylphenidate Hydrochloride Modified Release in Adults With Attention Deficit/Hyperactivity Disorder
A 6-month, Open-label Extension to a 40-week, Randomized, Double-blind, Placebo-controlled, Multicenter Efficacy and Safety Study of Methylphenidate Hydrochloride Modified Release in the Treatment of Adult Patients With Childhood-onset ADHD
Status: Enrolling
Updated: 11/13/2012
Novartis Investigative Site
mi
from
Miami, FL
Click here to add this to my saved trials
Open-label Extension Evaluating Methylphenidate Hydrochloride Modified Release in Adults With Attention Deficit/Hyperactivity Disorder
A 6-month, Open-label Extension to a 40-week, Randomized, Double-blind, Placebo-controlled, Multicenter Efficacy and Safety Study of Methylphenidate Hydrochloride Modified Release in the Treatment of Adult Patients With Childhood-onset ADHD
Status: Enrolling
Updated:  11/13/2012
Novartis Investigative Site
mi
from
Chicago, IL
Open-label Extension Evaluating Methylphenidate Hydrochloride Modified Release in Adults With Attention Deficit/Hyperactivity Disorder
A 6-month, Open-label Extension to a 40-week, Randomized, Double-blind, Placebo-controlled, Multicenter Efficacy and Safety Study of Methylphenidate Hydrochloride Modified Release in the Treatment of Adult Patients With Childhood-onset ADHD
Status: Enrolling
Updated: 11/13/2012
Novartis Investigative Site
mi
from
Chicago, IL
Click here to add this to my saved trials
Open-label Extension Evaluating Methylphenidate Hydrochloride Modified Release in Adults With Attention Deficit/Hyperactivity Disorder
A 6-month, Open-label Extension to a 40-week, Randomized, Double-blind, Placebo-controlled, Multicenter Efficacy and Safety Study of Methylphenidate Hydrochloride Modified Release in the Treatment of Adult Patients With Childhood-onset ADHD
Status: Enrolling
Updated:  11/13/2012
Novartis Investigative Site
mi
from
Louisville, KY
Open-label Extension Evaluating Methylphenidate Hydrochloride Modified Release in Adults With Attention Deficit/Hyperactivity Disorder
A 6-month, Open-label Extension to a 40-week, Randomized, Double-blind, Placebo-controlled, Multicenter Efficacy and Safety Study of Methylphenidate Hydrochloride Modified Release in the Treatment of Adult Patients With Childhood-onset ADHD
Status: Enrolling
Updated: 11/13/2012
Novartis Investigative Site
mi
from
Louisville, KY
Click here to add this to my saved trials
Open-label Extension Evaluating Methylphenidate Hydrochloride Modified Release in Adults With Attention Deficit/Hyperactivity Disorder
A 6-month, Open-label Extension to a 40-week, Randomized, Double-blind, Placebo-controlled, Multicenter Efficacy and Safety Study of Methylphenidate Hydrochloride Modified Release in the Treatment of Adult Patients With Childhood-onset ADHD
Status: Enrolling
Updated:  11/13/2012
Novartis Investigative Site
mi
from
Ann Arbor, MI
Open-label Extension Evaluating Methylphenidate Hydrochloride Modified Release in Adults With Attention Deficit/Hyperactivity Disorder
A 6-month, Open-label Extension to a 40-week, Randomized, Double-blind, Placebo-controlled, Multicenter Efficacy and Safety Study of Methylphenidate Hydrochloride Modified Release in the Treatment of Adult Patients With Childhood-onset ADHD
Status: Enrolling
Updated: 11/13/2012
Novartis Investigative Site
mi
from
Ann Arbor, MI
Click here to add this to my saved trials
Open-label Extension Evaluating Methylphenidate Hydrochloride Modified Release in Adults With Attention Deficit/Hyperactivity Disorder
A 6-month, Open-label Extension to a 40-week, Randomized, Double-blind, Placebo-controlled, Multicenter Efficacy and Safety Study of Methylphenidate Hydrochloride Modified Release in the Treatment of Adult Patients With Childhood-onset ADHD
Status: Enrolling
Updated:  11/13/2012
Novartis Investigative Site
mi
from
Las Vegas, NV
Open-label Extension Evaluating Methylphenidate Hydrochloride Modified Release in Adults With Attention Deficit/Hyperactivity Disorder
A 6-month, Open-label Extension to a 40-week, Randomized, Double-blind, Placebo-controlled, Multicenter Efficacy and Safety Study of Methylphenidate Hydrochloride Modified Release in the Treatment of Adult Patients With Childhood-onset ADHD
Status: Enrolling
Updated: 11/13/2012
Novartis Investigative Site
mi
from
Las Vegas, NV
Click here to add this to my saved trials
Open-label Extension Evaluating Methylphenidate Hydrochloride Modified Release in Adults With Attention Deficit/Hyperactivity Disorder
A 6-month, Open-label Extension to a 40-week, Randomized, Double-blind, Placebo-controlled, Multicenter Efficacy and Safety Study of Methylphenidate Hydrochloride Modified Release in the Treatment of Adult Patients With Childhood-onset ADHD
Status: Enrolling
Updated:  11/13/2012
Novartis Investigative Site
mi
from
Brick, NJ
Open-label Extension Evaluating Methylphenidate Hydrochloride Modified Release in Adults With Attention Deficit/Hyperactivity Disorder
A 6-month, Open-label Extension to a 40-week, Randomized, Double-blind, Placebo-controlled, Multicenter Efficacy and Safety Study of Methylphenidate Hydrochloride Modified Release in the Treatment of Adult Patients With Childhood-onset ADHD
Status: Enrolling
Updated: 11/13/2012
Novartis Investigative Site
mi
from
Brick, NJ
Click here to add this to my saved trials
Open-label Extension Evaluating Methylphenidate Hydrochloride Modified Release in Adults With Attention Deficit/Hyperactivity Disorder
A 6-month, Open-label Extension to a 40-week, Randomized, Double-blind, Placebo-controlled, Multicenter Efficacy and Safety Study of Methylphenidate Hydrochloride Modified Release in the Treatment of Adult Patients With Childhood-onset ADHD
Status: Enrolling
Updated:  11/13/2012
Novartis Investigative Site
mi
from
Bismark, ND
Open-label Extension Evaluating Methylphenidate Hydrochloride Modified Release in Adults With Attention Deficit/Hyperactivity Disorder
A 6-month, Open-label Extension to a 40-week, Randomized, Double-blind, Placebo-controlled, Multicenter Efficacy and Safety Study of Methylphenidate Hydrochloride Modified Release in the Treatment of Adult Patients With Childhood-onset ADHD
Status: Enrolling
Updated: 11/13/2012
Novartis Investigative Site
mi
from
Bismark, ND
Click here to add this to my saved trials
Open-label Extension Evaluating Methylphenidate Hydrochloride Modified Release in Adults With Attention Deficit/Hyperactivity Disorder
A 6-month, Open-label Extension to a 40-week, Randomized, Double-blind, Placebo-controlled, Multicenter Efficacy and Safety Study of Methylphenidate Hydrochloride Modified Release in the Treatment of Adult Patients With Childhood-onset ADHD
Status: Enrolling
Updated:  11/13/2012
Novartis Investigative Site
mi
from
Cincinatti, OH
Open-label Extension Evaluating Methylphenidate Hydrochloride Modified Release in Adults With Attention Deficit/Hyperactivity Disorder
A 6-month, Open-label Extension to a 40-week, Randomized, Double-blind, Placebo-controlled, Multicenter Efficacy and Safety Study of Methylphenidate Hydrochloride Modified Release in the Treatment of Adult Patients With Childhood-onset ADHD
Status: Enrolling
Updated: 11/13/2012
Novartis Investigative Site
mi
from
Cincinatti, OH
Click here to add this to my saved trials
Open-label Extension Evaluating Methylphenidate Hydrochloride Modified Release in Adults With Attention Deficit/Hyperactivity Disorder
A 6-month, Open-label Extension to a 40-week, Randomized, Double-blind, Placebo-controlled, Multicenter Efficacy and Safety Study of Methylphenidate Hydrochloride Modified Release in the Treatment of Adult Patients With Childhood-onset ADHD
Status: Enrolling
Updated:  11/13/2012
Novartis Investigative Site
mi
from
Oklahoma City, OK
Open-label Extension Evaluating Methylphenidate Hydrochloride Modified Release in Adults With Attention Deficit/Hyperactivity Disorder
A 6-month, Open-label Extension to a 40-week, Randomized, Double-blind, Placebo-controlled, Multicenter Efficacy and Safety Study of Methylphenidate Hydrochloride Modified Release in the Treatment of Adult Patients With Childhood-onset ADHD
Status: Enrolling
Updated: 11/13/2012
Novartis Investigative Site
mi
from
Oklahoma City, OK
Click here to add this to my saved trials
Open-label Extension Evaluating Methylphenidate Hydrochloride Modified Release in Adults With Attention Deficit/Hyperactivity Disorder
A 6-month, Open-label Extension to a 40-week, Randomized, Double-blind, Placebo-controlled, Multicenter Efficacy and Safety Study of Methylphenidate Hydrochloride Modified Release in the Treatment of Adult Patients With Childhood-onset ADHD
Status: Enrolling
Updated:  11/13/2012
Novartis Investigative Site
mi
from
Blue Bell, PA
Open-label Extension Evaluating Methylphenidate Hydrochloride Modified Release in Adults With Attention Deficit/Hyperactivity Disorder
A 6-month, Open-label Extension to a 40-week, Randomized, Double-blind, Placebo-controlled, Multicenter Efficacy and Safety Study of Methylphenidate Hydrochloride Modified Release in the Treatment of Adult Patients With Childhood-onset ADHD
Status: Enrolling
Updated: 11/13/2012
Novartis Investigative Site
mi
from
Blue Bell, PA
Click here to add this to my saved trials
Open-label Extension Evaluating Methylphenidate Hydrochloride Modified Release in Adults With Attention Deficit/Hyperactivity Disorder
A 6-month, Open-label Extension to a 40-week, Randomized, Double-blind, Placebo-controlled, Multicenter Efficacy and Safety Study of Methylphenidate Hydrochloride Modified Release in the Treatment of Adult Patients With Childhood-onset ADHD
Status: Enrolling
Updated:  11/13/2012
Novartis Investigative site
mi
from
Dallas, TX
Open-label Extension Evaluating Methylphenidate Hydrochloride Modified Release in Adults With Attention Deficit/Hyperactivity Disorder
A 6-month, Open-label Extension to a 40-week, Randomized, Double-blind, Placebo-controlled, Multicenter Efficacy and Safety Study of Methylphenidate Hydrochloride Modified Release in the Treatment of Adult Patients With Childhood-onset ADHD
Status: Enrolling
Updated: 11/13/2012
Novartis Investigative site
mi
from
Dallas, TX
Click here to add this to my saved trials
Open-label Extension Evaluating Methylphenidate Hydrochloride Modified Release in Adults With Attention Deficit/Hyperactivity Disorder
A 6-month, Open-label Extension to a 40-week, Randomized, Double-blind, Placebo-controlled, Multicenter Efficacy and Safety Study of Methylphenidate Hydrochloride Modified Release in the Treatment of Adult Patients With Childhood-onset ADHD
Status: Enrolling
Updated:  11/13/2012
Novartis Investigative Site
mi
from
Spokane, WA
Open-label Extension Evaluating Methylphenidate Hydrochloride Modified Release in Adults With Attention Deficit/Hyperactivity Disorder
A 6-month, Open-label Extension to a 40-week, Randomized, Double-blind, Placebo-controlled, Multicenter Efficacy and Safety Study of Methylphenidate Hydrochloride Modified Release in the Treatment of Adult Patients With Childhood-onset ADHD
Status: Enrolling
Updated: 11/13/2012
Novartis Investigative Site
mi
from
Spokane, WA
Click here to add this to my saved trials
Extension Study of Asenapine {P06107 (NCT01244815)} for Pediatric Bipolar Disorder (P05898 AM3)
A 50-Week Open-Label, Flexible-Dose Trial of Asenapine Extension Treatment to P06107 in Pediatric Acute Manic or Mixed Episodes Associated With Bipolar I Disorder (Protocol No. P05898)
Status: Enrolling
Updated:  11/14/2012
Clinical Research Facility
mi
from
Dothan, AL
Extension Study of Asenapine {P06107 (NCT01244815)} for Pediatric Bipolar Disorder (P05898 AM3)
A 50-Week Open-Label, Flexible-Dose Trial of Asenapine Extension Treatment to P06107 in Pediatric Acute Manic or Mixed Episodes Associated With Bipolar I Disorder (Protocol No. P05898)
Status: Enrolling
Updated: 11/14/2012
Clinical Research Facility
mi
from
Dothan, AL
Click here to add this to my saved trials
Extension Study of Asenapine {P06107 (NCT01244815)} for Pediatric Bipolar Disorder (P05898 AM3)
A 50-Week Open-Label, Flexible-Dose Trial of Asenapine Extension Treatment to P06107 in Pediatric Acute Manic or Mixed Episodes Associated With Bipolar I Disorder (Protocol No. P05898)
Status: Enrolling
Updated:  11/14/2012
Clinical Research Facility
mi
from
Little Rock, AR
Extension Study of Asenapine {P06107 (NCT01244815)} for Pediatric Bipolar Disorder (P05898 AM3)
A 50-Week Open-Label, Flexible-Dose Trial of Asenapine Extension Treatment to P06107 in Pediatric Acute Manic or Mixed Episodes Associated With Bipolar I Disorder (Protocol No. P05898)
Status: Enrolling
Updated: 11/14/2012
Clinical Research Facility
mi
from
Little Rock, AR
Click here to add this to my saved trials
Extension Study of Asenapine {P06107 (NCT01244815)} for Pediatric Bipolar Disorder (P05898 AM3)
A 50-Week Open-Label, Flexible-Dose Trial of Asenapine Extension Treatment to P06107 in Pediatric Acute Manic or Mixed Episodes Associated With Bipolar I Disorder (Protocol No. P05898)
Status: Enrolling
Updated:  11/14/2012
Clinical Research Facility
mi
from
Anaheim, CA
Extension Study of Asenapine {P06107 (NCT01244815)} for Pediatric Bipolar Disorder (P05898 AM3)
A 50-Week Open-Label, Flexible-Dose Trial of Asenapine Extension Treatment to P06107 in Pediatric Acute Manic or Mixed Episodes Associated With Bipolar I Disorder (Protocol No. P05898)
Status: Enrolling
Updated: 11/14/2012
Clinical Research Facility
mi
from
Anaheim, CA
Click here to add this to my saved trials
Extension Study of Asenapine {P06107 (NCT01244815)} for Pediatric Bipolar Disorder (P05898 AM3)
A 50-Week Open-Label, Flexible-Dose Trial of Asenapine Extension Treatment to P06107 in Pediatric Acute Manic or Mixed Episodes Associated With Bipolar I Disorder (Protocol No. P05898)
Status: Enrolling
Updated:  11/14/2012
Clinical Research Facility
mi
from
Colton, CA
Extension Study of Asenapine {P06107 (NCT01244815)} for Pediatric Bipolar Disorder (P05898 AM3)
A 50-Week Open-Label, Flexible-Dose Trial of Asenapine Extension Treatment to P06107 in Pediatric Acute Manic or Mixed Episodes Associated With Bipolar I Disorder (Protocol No. P05898)
Status: Enrolling
Updated: 11/14/2012
Clinical Research Facility
mi
from
Colton, CA
Click here to add this to my saved trials
Extension Study of Asenapine {P06107 (NCT01244815)} for Pediatric Bipolar Disorder (P05898 AM3)
A 50-Week Open-Label, Flexible-Dose Trial of Asenapine Extension Treatment to P06107 in Pediatric Acute Manic or Mixed Episodes Associated With Bipolar I Disorder (Protocol No. P05898)
Status: Enrolling
Updated:  11/14/2012
Clinical Research Facility
mi
from
Costa Mesa, CA
Extension Study of Asenapine {P06107 (NCT01244815)} for Pediatric Bipolar Disorder (P05898 AM3)
A 50-Week Open-Label, Flexible-Dose Trial of Asenapine Extension Treatment to P06107 in Pediatric Acute Manic or Mixed Episodes Associated With Bipolar I Disorder (Protocol No. P05898)
Status: Enrolling
Updated: 11/14/2012
Clinical Research Facility
mi
from
Costa Mesa, CA
Click here to add this to my saved trials
Extension Study of Asenapine {P06107 (NCT01244815)} for Pediatric Bipolar Disorder (P05898 AM3)
A 50-Week Open-Label, Flexible-Dose Trial of Asenapine Extension Treatment to P06107 in Pediatric Acute Manic or Mixed Episodes Associated With Bipolar I Disorder (Protocol No. P05898)
Status: Enrolling
Updated:  11/14/2012
Clinical Research Facility
mi
from
Escondido, CA
Extension Study of Asenapine {P06107 (NCT01244815)} for Pediatric Bipolar Disorder (P05898 AM3)
A 50-Week Open-Label, Flexible-Dose Trial of Asenapine Extension Treatment to P06107 in Pediatric Acute Manic or Mixed Episodes Associated With Bipolar I Disorder (Protocol No. P05898)
Status: Enrolling
Updated: 11/14/2012
Clinical Research Facility
mi
from
Escondido, CA
Click here to add this to my saved trials
Extension Study of Asenapine {P06107 (NCT01244815)} for Pediatric Bipolar Disorder (P05898 AM3)
A 50-Week Open-Label, Flexible-Dose Trial of Asenapine Extension Treatment to P06107 in Pediatric Acute Manic or Mixed Episodes Associated With Bipolar I Disorder (Protocol No. P05898)
Status: Enrolling
Updated:  11/14/2012
Clinical Research Facility
mi
from
Murrieta, CA
Extension Study of Asenapine {P06107 (NCT01244815)} for Pediatric Bipolar Disorder (P05898 AM3)
A 50-Week Open-Label, Flexible-Dose Trial of Asenapine Extension Treatment to P06107 in Pediatric Acute Manic or Mixed Episodes Associated With Bipolar I Disorder (Protocol No. P05898)
Status: Enrolling
Updated: 11/14/2012
Clinical Research Facility
mi
from
Murrieta, CA
Click here to add this to my saved trials
Extension Study of Asenapine {P06107 (NCT01244815)} for Pediatric Bipolar Disorder (P05898 AM3)
A 50-Week Open-Label, Flexible-Dose Trial of Asenapine Extension Treatment to P06107 in Pediatric Acute Manic or Mixed Episodes Associated With Bipolar I Disorder (Protocol No. P05898)
Status: Enrolling
Updated:  11/14/2012
Clinical Research Facility
mi
from
Mission Hills, CA
Extension Study of Asenapine {P06107 (NCT01244815)} for Pediatric Bipolar Disorder (P05898 AM3)
A 50-Week Open-Label, Flexible-Dose Trial of Asenapine Extension Treatment to P06107 in Pediatric Acute Manic or Mixed Episodes Associated With Bipolar I Disorder (Protocol No. P05898)
Status: Enrolling
Updated: 11/14/2012
Clinical Research Facility
mi
from
Mission Hills, CA
Click here to add this to my saved trials
Extension Study of Asenapine {P06107 (NCT01244815)} for Pediatric Bipolar Disorder (P05898 AM3)
A 50-Week Open-Label, Flexible-Dose Trial of Asenapine Extension Treatment to P06107 in Pediatric Acute Manic or Mixed Episodes Associated With Bipolar I Disorder (Protocol No. P05898)
Status: Enrolling
Updated:  11/14/2012
Clinical Research Facility
mi
from
San Diego, CA
Extension Study of Asenapine {P06107 (NCT01244815)} for Pediatric Bipolar Disorder (P05898 AM3)
A 50-Week Open-Label, Flexible-Dose Trial of Asenapine Extension Treatment to P06107 in Pediatric Acute Manic or Mixed Episodes Associated With Bipolar I Disorder (Protocol No. P05898)
Status: Enrolling
Updated: 11/14/2012
Clinical Research Facility
mi
from
San Diego, CA
Click here to add this to my saved trials
Extension Study of Asenapine {P06107 (NCT01244815)} for Pediatric Bipolar Disorder (P05898 AM3)
A 50-Week Open-Label, Flexible-Dose Trial of Asenapine Extension Treatment to P06107 in Pediatric Acute Manic or Mixed Episodes Associated With Bipolar I Disorder (Protocol No. P05898)
Status: Enrolling
Updated:  11/14/2012
Clinical Research Facility
mi
from
Irvine, CA
Extension Study of Asenapine {P06107 (NCT01244815)} for Pediatric Bipolar Disorder (P05898 AM3)
A 50-Week Open-Label, Flexible-Dose Trial of Asenapine Extension Treatment to P06107 in Pediatric Acute Manic or Mixed Episodes Associated With Bipolar I Disorder (Protocol No. P05898)
Status: Enrolling
Updated: 11/14/2012
Clinical Research Facility
mi
from
Irvine, CA
Click here to add this to my saved trials
Extension Study of Asenapine {P06107 (NCT01244815)} for Pediatric Bipolar Disorder (P05898 AM3)
A 50-Week Open-Label, Flexible-Dose Trial of Asenapine Extension Treatment to P06107 in Pediatric Acute Manic or Mixed Episodes Associated With Bipolar I Disorder (Protocol No. P05898)
Status: Enrolling
Updated:  11/14/2012
Clinical Research Facility
mi
from
Santa Ana, CA
Extension Study of Asenapine {P06107 (NCT01244815)} for Pediatric Bipolar Disorder (P05898 AM3)
A 50-Week Open-Label, Flexible-Dose Trial of Asenapine Extension Treatment to P06107 in Pediatric Acute Manic or Mixed Episodes Associated With Bipolar I Disorder (Protocol No. P05898)
Status: Enrolling
Updated: 11/14/2012
Clinical Research Facility
mi
from
Santa Ana, CA
Click here to add this to my saved trials
Extension Study of Asenapine {P06107 (NCT01244815)} for Pediatric Bipolar Disorder (P05898 AM3)
A 50-Week Open-Label, Flexible-Dose Trial of Asenapine Extension Treatment to P06107 in Pediatric Acute Manic or Mixed Episodes Associated With Bipolar I Disorder (Protocol No. P05898)
Status: Enrolling
Updated:  11/14/2012
Clinical Research Facility
mi
from
San Francisco, CA
Extension Study of Asenapine {P06107 (NCT01244815)} for Pediatric Bipolar Disorder (P05898 AM3)
A 50-Week Open-Label, Flexible-Dose Trial of Asenapine Extension Treatment to P06107 in Pediatric Acute Manic or Mixed Episodes Associated With Bipolar I Disorder (Protocol No. P05898)
Status: Enrolling
Updated: 11/14/2012
Clinical Research Facility
mi
from
San Francisco, CA
Click here to add this to my saved trials
Extension Study of Asenapine {P06107 (NCT01244815)} for Pediatric Bipolar Disorder (P05898 AM3)
A 50-Week Open-Label, Flexible-Dose Trial of Asenapine Extension Treatment to P06107 in Pediatric Acute Manic or Mixed Episodes Associated With Bipolar I Disorder (Protocol No. P05898)
Status: Enrolling
Updated:  11/14/2012
Clinical Research Facility
mi
from
Colorado Springs, CO
Extension Study of Asenapine {P06107 (NCT01244815)} for Pediatric Bipolar Disorder (P05898 AM3)
A 50-Week Open-Label, Flexible-Dose Trial of Asenapine Extension Treatment to P06107 in Pediatric Acute Manic or Mixed Episodes Associated With Bipolar I Disorder (Protocol No. P05898)
Status: Enrolling
Updated: 11/14/2012
Clinical Research Facility
mi
from
Colorado Springs, CO
Click here to add this to my saved trials
Extension Study of Asenapine {P06107 (NCT01244815)} for Pediatric Bipolar Disorder (P05898 AM3)
A 50-Week Open-Label, Flexible-Dose Trial of Asenapine Extension Treatment to P06107 in Pediatric Acute Manic or Mixed Episodes Associated With Bipolar I Disorder (Protocol No. P05898)
Status: Enrolling
Updated:  11/14/2012
Clinical Research Facility
mi
from
Hartford, CT
Extension Study of Asenapine {P06107 (NCT01244815)} for Pediatric Bipolar Disorder (P05898 AM3)
A 50-Week Open-Label, Flexible-Dose Trial of Asenapine Extension Treatment to P06107 in Pediatric Acute Manic or Mixed Episodes Associated With Bipolar I Disorder (Protocol No. P05898)
Status: Enrolling
Updated: 11/14/2012
Clinical Research Facility
mi
from
Hartford, CT
Click here to add this to my saved trials